EUVIMEDEUVIMED entdecken
Crossref

Tirzepatide: the most Effective Drug Therapy for Prevention of type 2 Diabetes

Nasser Mikhail

Clinical Endocrinology and Metabolism · 20.02.2025 · 04 (01) · 01-06

DOI: 10.31579/2834-8761/073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology and Metabolism, online erschienen am 20.02.2025. Verfasst von Nasser Mikhail.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a main trigger for development of type 2 diabetes. Tirzepatide is a dual receptor agonist of glucagon-like 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and is a potent agent for controlling glycemic control and reducing body weight. Accordingly, tirzepatide was evaluated in addition to lifestyle changes to decrease incidence of type 2 diabetes in obese subjects with obesity and prediabetes in an extension study of the SURMOUNT-1 trial. The latter was a randomized, double-blind trial of 72 weeks to evaluate the effects of tirzepatide on weight reduction in 2,539 participants with obesity; 40% (n=1,032) of those subjects had prediabetes. The authors of SURMOUNT-1 study examined the frequency of new-onset type 2 diabetes in the 1,032 subjects with pre-diabetes from baseline to week 176 and week 193 after a 17-week off tirzepatide or placebo. After 176 weeks, type 2 diabetes was diagnosed in 1.5% (n=4), 2.0% (n=5), 0.4% (n=1), and 13.3% (n=36) in subjects randomized to tirzepatide 5 mg, 10 mg, and 15 mg, and placebo, respectively. At 176 weeks, compared with placebo, risk of type 2 diabetes in the pooled tirzepatide groups, was decreased by 93%; hazard ratio (HR) 0.07, 95% CI, 0.0 to 0.1; P

Zitieren

APA

Mikhail, N. (2025). Tirzepatide: the most Effective Drug Therapy for Prevention of type 2 Diabetes. Clinical Endocrinology and Metabolism, 04(01), 01-06. https://doi.org/10.31579/2834-8761/073

Vancouver

Mikhail N. Tirzepatide: the most Effective Drug Therapy for Prevention of type 2 Diabetes. Clinical Endocrinology and Metabolism. 2025;04(01):01-06. doi:10.31579/2834-8761/073

BibTeX
@article{Mikhail2025,
  author = {Mikhail, Nasser},
  title = {Tirzepatide: the most Effective Drug Therapy for Prevention of type 2 Diabetes},
  journal = {Clinical Endocrinology and Metabolism},
  year = {2025},
  volume = {04},
  number = {01},
  pages = {01--06},
  doi = {10.31579/2834-8761/073}
}
Kostenlos starten →